Omeros Corporation Share Price & Technical Analysis
OMER · $11.46 (-4.18%)
Healthcare / Biotechnology
$11.46
-4.18%
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinica…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-21% return in May, -15% avg return in past 3 year May month.
-31% return in 2026, 151% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -33% | 4% | -10% | 29% | -21% | – | – | – | – | – | – | – | -31% |
| 25 | -13% | 0% | -2% | -21% | -58% | -3% | 30% | 11% | 0% | 78% | 35% | 76% | 131% |
| 24 | 0% | 29% | -22% | -6% | 6% | 21% | 32% | -21% | -2% | 3% | 178% | -12% | 205% |
| 23 | 26% | 31% | 27% | 23% | 7% | -11% | -20% | -20% | -19% | -59% | 83% | 50% | 117% |
| 22 | -9% | 18% | -15% | -43% | -29% | 12% | 79% | -17% | -20% | 0% | -38% | 5% | -58% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.06B
P/E ratio
—
52W high
$17.65
52W low
$2.95
Volume
15,25,924
Beta
2.66
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Omeros Corporation share price today?
- Omeros Corporation (OMER) last traded around $11.46 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OMER have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OMER. Download the app for real-time alerts.
- How can I analyze Omeros Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.